Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD6422 in advanced or metastatic CLDN18.2+ GI tumors
NCT05981235Phase 1Completed
- Sponsor
- Peking University
- Start
- Dec 2023
- Primary completion
- Jun 2025
- Modality
- Autologous CAR-T
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AZD6422 in gastrointestinal adenocarcinoma (GIAC), sponsored by Peking University. Primary endpoints: Incidence of treatment-emergent adverse events, adverse events of special interest, and serious adverse events at 24 months, Occurrence of Dose limiting toxicity at 28 days and 1 more. Started Dec 2023; status: completed.
02
Drugs
AZD6422
03
Conditions
gastrointestinal adenocarcinoma (GIAC)
Beyond the preview
Go deeper on NCT05981235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05981235.